Lannett Company (NYSE:LCI) is set to meet
with the FDA on June 9, 2020 to plan the next steps for the clinical
advancement of its biosimilar insulin glargine partnered product
candidate.
Insulin glargine is used to treat adults with Type 2 diabetes, as well as adults and pediatric patients with Type 1 diabetes.
https://seekingalpha.com/news/3559302-lannett-to-meet-fda-on-biosimilar-insulin
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.